Depression and degree of acceptance of adjuvant cytotoxic drugs
Abstract
An interaction between psychological attitude and outcome in early-stage breast cancer has been postulated, with a possible explanation related to the presumed tendency of depressed patients to be less proactive in obtaining health care. We report on the degree of acceptance of adjuvant chemotherapy in patients with breast cancer who have concomitant depression. Only 20 (51.3%) of the study group accepted and received the proposed chemotherapy compared with 75 (92.2%) of the control group (p<0.0001). Treatment of depression might be essential for tailoring adjuvant treatments with chemotherapy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Depression and anxiety symptoms in people living with breast cancer are associated with poorer physical health, more pain and fatigue, more substance use, poorer quality of life, less acceptance and compliance with adjuvant treatments, higher prevalence of metastasis, higher risk of relapse and mortality, as well as lower survival time.
“Depression and anxiety symptoms in people living with breast cancer are associated with poorer physical health, more pain and fatigue, more substance use, poorer quality of life, less acceptance and compliance with adjuvant treatments, higher prevalence of metastasis, higher risk of relapse and mortality, as well as lower survival time”
MDD may reduce treatment adherence or initiation in people with cancer.
“Some studies have also reported that MDD may predict lower T-cell cytokine expression and reduce treatment adherence or initiation87,88, while improvement in depressive symptoms has been associated with increased survival in people with cancer89.”
From Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management (2023) · cites this paper as [88]
MDD may predict lower T-cell cytokine expression.
“Some studies have also reported that MDD may predict lower T-cell cytokine expression and reduce treatment adherence or initiation87,88, while improvement in depressive symptoms has been associated with increased survival in people with cancer89.”
From Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management (2023) · cites this paper as [88]
The citation lists haven’t been fetched yet
References 8 · Cited by 351
- Authors
- Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., & Goldhirsch, A.
- Affiliations
- European Institute of Oncology (IT)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-10
- Volume
- 356
- Issue
- 9238
- Pages
- 1326-1327
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1965295590
- Cited by
- 351
- References
- 8
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 14 · 2023: 20 · 2022: 16 · 2021: 16 · 2020: 21 · 2019: 22 · 2018: 18 · 2017: 16 · 2016: 24 · 2015: 28 · 2014: 16 · 2013: 17 · 2012: 19
- FWCI
- 2.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Health Professions › General Health Professions › Patient-Provider Communication in Healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Keywords
- depression, breast cancer, adjuvant chemotherapy, treatment acceptance, early breast cancer, treatment-seeking behavior, depression treatment
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclophosphamide, Depression, Drug Administration Schedule, Female, Fluorouracil, Humans, Methotrexate, Middle Aged, Patient Acceptance of Health Care, Retrospective Studies, Logistic Models, Case-Control Studies, Chemotherapy, Adjuvant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
